Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA-approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotan, Tamara L., Kaur, Harsimar B., Salles, Daniela, Murali, Sanjana, Schaeffer, Edward M., Lanchbury, Jerry S., Isaacs, William B., Brown, Robert, Richardson, Andrea L., Cussenot, Olivier, Cancel-Tassin, Geraldine, Timms, Kirsten M., Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154637/
https://www.ncbi.nlm.nih.gov/pubmed/33462368
http://dx.doi.org/10.1038/s41379-020-00731-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154637/
https://www.ncbi.nlm.nih.gov/pubmed/33462368
http://dx.doi.org/10.1038/s41379-020-00731-4

Ejemplares similares